The diagnosis and management of Ewing sarcoma is laborious and requires the correlation of multiple imaging modalities. This is an aggressive, malignant tumor of bone and soft tissue. Ewing sarcoma rarely affects individuals older than 20 years of age. Clinical symptoms are variable and nonspecific. Biopsy is the only definitive diagnosis. Multimodality medical imaging plays a great role in visualizing the tumor, documenting metastatic spread, tumor staging, associated complications, and response to therapy. Standard treatment of Ewing sarcoma is a multimodal therapeutic regimen, including chemotherapy, surgery, and radiation. Prognosis depends on tumor location, presence of metastases, and tumor size.
Etiology
Researchers are gathering clinical data to understand this disease process. Predominately a primary cancer, there is very low incidence occurring as a secondary malignancy. 4, 5 Primary metastases in lung, bone, bone marrow, or a combination of these are detectable in approximately 25% of patients at the time of diagnosis. 6 The liver, central nervous system, and lymph nodes are affected less by metastatic disease. 6 The site of the primary Ewing sarcoma usually shows a relationship to the presence of metastatic disease at the time of diagnosis. 5 According to data gathered, metastatic disease occurs more frequently in patients with the following criteria: a primary tumor of the pelvis, age older than 12 years, elevated levels of lactic dehydrogenase, anemia, fever, tumor volume greater than 150 mL, and less than 2 months between onset of symptoms and diagnosis. 7
Presentation
The Ewing family of tumors (EFT) is a group of cancers that start in the bones or nearby soft tissues and share common features. The family includes Ewing sarcoma of bone, extraosseous Ewing tumor (EOE), and peripheral primitive neuroectodermal tumor (PPNET). PPNETs that start in the chest wall are known as Askin tumors. 4 The Ewing sarcoma of bone is the most common tumor in this family. James Ewing first described it in 1921 as a tumor of the shaft of long bones that was radiosensitive. 5 Ewing sarcoma is primarily a cancer affecting children and young adults. Although any age group may be affected, approximately 80% of patients affected are younger than 20 years of age. 2 There is no sex difference until 13 years of age; thereafter, there is an increased incidence among males. 3 A difference in incidence exists among ethnic groups, with whites more frequently affected; it is uncommonly reported among Asians and rarely reported in the black population. 2 As stated by Iwamoto 2 in the Surveillance, Epidemiology, and End Results (SEER) program, in the United States between 1973 and 1985, only 3 of 650 cases of Ewing sarcoma occurred in black patients. Ewing sarcoma is not inherited or associated with congenital diseases. 5 The most common sites are the pelvic bones, the long bones of the lower extremities, and the bones of the chest wall. 6 In the trunk, the tumor most often occurs in the pelvis, followed by the scapula, vertebral column, ribs, and clavicle. 2 Of the long bones, the femur is most commonly attacked, followed by the humerus, tibia, and the bones of the forearm. 2 Approximately 50% of cases of Ewing sarcoma involve the pelvis. 3
Clinical Presentation
The earliest symptom is pain. 2 Localized pain is present in 85% of children, and localized swelling is seen in 60%. 5 The swelling is tense, elastic, hard, tender, rapidly increasing, and accompanied by local heat. 2 Sonography may be useful in evaluating such areas, as shown in Figures 1 and 2 . Patients may also present with fever, weight loss, and increased sedimentation rate. 5 Other symptoms include decreased appetite, fatigue, paralysis and/or incontinence, or symptoms related to nerve compression from the tumor. 1
Pathology and Genetic Characterization
Researchers agree that Ewing sarcoma is a developmental tumor that is activated at some point in childhood, but it is not known in which embryonic layer the tumor is seeded. 8 The Ewing tumor expresses proteins that suggest it is derived from the ectoderm. 8 The EFTs all have translocations involving the EWSR1 gene. 9, 10 The official name of this gene is "Ewing sarcoma breakpoint region 1," also known as EWS or bk984G1.4. 10 Mutations in this gene, typically at the t(11;22)(q24;q12) translocation, have been shown to cause Ewing sarcoma. 10 The chromosomal translocation between chromosomes 11 and 22 is present in approximately 85% of Ewing tumors. 6 French scientists discovered a protein unique to Ewing sarcoma: a two-headed chimera of the proteins EWS and FLI1. 8 This abnormal protein is growth promoting in culture and a likely causative factor of Ewing sarcoma. 8 In their normal state, both EWS and FLI1 are necessary transcription factors. 8 EFTs are small, round cell tumors 5 histologically arranged in sheets as a homogeneous population of small, round cells with high nuclear to cytoplasmic ratios. 2 The cytoplasm is scant and pale in contrast to the nuclei, which are clearly visualized by their intense color. 2 Mitotic activity is usually low, and cytoplasmic glycogen is usually present. 6 Cytogenic or immunohistochemical studies often are required to differentiate Ewing sarcoma from other round cell tumors. 2 Other cancers in this group include neuroblastoma, rhabdomyosarcoma, and non-Hodgkin lymphoma. 5 The most commonly used diagnostic marker is CD99, also known as MIC2. 11 CD99 is a 32-kDa membrane glycoprotein highly expressed in most cases; however, the expression is not unique to Ewing sarcoma. 11, 12 CD99 plays a role in several biological processes, including cell adhesion, migration, and apoptosis; differentiation of T cells; and maintenance of cellular morphology. 11 Immunohistochemical staining for the MIC2 gene product is positive in 90% of cases. 2 Concurrent positivity for membrane CD99 and FLI1 strongly supports a diagnosis of EFT. 13 Molecular diagnosis using either fluorescent in situ hybridization (FISH) or reverse transcriptase-polymerase chain reaction (RT-PCR) is now a routine part of a pathological examination. 14, 15 FISH is a laboratory technique to detect and locate a specific DNA sequence on a chromosome. 14 This is performed by exposing chromosomes to a specific DNA sequence, a probe that has a fluorescent molecule attached to it; the probe sequence binds to the corresponding sequence on the chromosome. 15 Using FISH, a new biopsy or operation specimen can provide diagnostic data in 5 to 10 business days. 16 Because the FISH technique may result in false-positive or false-negative samples, it should be performed in conjunction with other cytogenic analyses such as RT-PCR. 12 The application of RT-PCR, which detects and quantifies mRNA, is used for initial differential diagnosis and detection of minimal residual disease, circulating tumor cells, and occult marrow disease. 2 RT-PCR accurately detects EWS-FLI1 translocations by using small tissue amounts. 13
Diagnosis
Diagnostic procedures include complete medical history, physical examination, multiple imaging studies, biopsy, bone marrow aspiration, and blood tests. The initial imaging is done by radiograph of the suspicious area in two planes. 2 Tumor-related osteolysis and periosteal reactions suggest a primary malignant tumor. 2 A type of periosteal reaction is the "onion skin" appearance, which is a prominent multilayered reaction. 17 The onion skin periostitis is classic for Ewing sarcoma. 17 A typical Ewing sarcoma appears ill defined, or a focally moth-eaten lesion accompanied by a periosteal reaction that affects the diaphyses of long bones. 2 Magnetic resonance imaging (MRI) offers the most precise definition of the local extent of bone tumors, including the degree of extension into the intermedullary portion and the relationship of the neoplasm to adjacent blood vessels and nerves. 2 Nuclear medicine bone scans are useful to detect bone and metastatic tumors. 1 Recent studies show that positron emission tomography/computed tomography (PET/CT) provides more valuable information than MRI for assessing therapeutic responses. 2 Venous Doppler sonography of the lower extremities may show decreased response to augmentation and the Valsalva maneuver, which may increase suspicion of abdominal pathology. 18 Abdominal sonography may visualize the mass and evaluate nearby vessels for mass effects such as compression. 18 A sonogram performed with the HDI 5000 (Philips Medical, Bothell, WA) shows a large pelvic mass that displaces the urinary bladder to the right (Figure 3 ). A tumor complication may be compression of the urinary system. Sonography can verify patency of ureteral jets, as shown in Figure 4 .
For most malignancies, the definitive diagnostic test is biopsy. Sonography-guided fine-needle aspiration or core needle biopsy can be diagnostic; however, the most adequate method is by open biopsy. 6 Bone marrow aspiration can examine the number, size, and maturity of blood cells and/or cancer cells. 1 No blood, serum, or urine test is specific to identify Ewing sarcoma. 6 Labs may show nonspecific signs of inflammation, such as elevated erythrocyte sedimentation rate, moderate anemia, or leukocytosis. 6 Elevated levels of serum lactate dehydrogenase correlate with tumor burden in general, not specifically with Ewing sarcoma. 6 Initial symptoms clinically mistaken can delay diagnosis. The majority of affected individuals are physically active, and pain is often mistaken for bone growth or injuries resulting from sport or everyday activities. 6 Musculoskeletal symptoms that are due to the tumor may lead the patient to clinicians who are not familiar with malignancies or experienced in dealing with them. 18 Pain is expected to be continuous and worsen at night; however, in more than 80% of cases, the pain is intermittent, strain related, and not bothersome at night, as in benign musculoskeletal conditions. 18 The duration of symptoms prior to definitive diagnosis can be weeks to months, with a median of 3 to 9 months. 6 The intermittent course of Ewing sarcoma versus the expectation of a steady progression is a major factor for delayed diagnosis. 18
Staging
Once diagnosis is determined, the tumor is staged. The staging process will determine the extent of tumor spread. Tumor stage will also suggest which treatment will be most beneficial and gives an indication of prognosis. 1 The American Joint Committee on Cancer (AJCC) has specific staging systems for most cancers. If the Ewing tumor originates in bone, the AJCC bone staging system is used, but if the tumor is extraosseous, the soft tissue staging system is employed. 4 Soft tissue sarcomas are staged according to the TNM system (T for tumor size, N for spread to lymph nodes, and M for metastasis). 4 An additional factor, the grade (G), is also used. 4 Grade is determined by cell differentiation, mitotic count, and tumor necrosis. 4 The higher the grade, the faster tumors will grow and spread. The T, N, M, and G are combined into a process called stage grouping to assign a soft tissue sarcoma stage. 4 The AJCC staging for bone cancer is also done on a TNM basis, with G being low or high grade. 4 All Ewing bone tumors are classified as high grade. 4 Using the AJCC system for bone cancer, stage IIA lesions are confined within well-defined anatomical compartments, or the tumor is not larger than the bone it is affecting. 4 Stage IIB lesions extend beyond their compartment of origin, whereas stage III lesions have metastasized regardless of the size of the tumor. 4 In clinical settings, clinicians rely on a more simple staging system: localized versus metastatic. 4 Staging with MRI, the clinician can visualize the exact location and extent of the cancer, often eliminating the need for total limb amputation. 17 Diagnostic staging should include CT of the chest to determine pulmonary metastases, and a whole-body bone scan should be done to document or exclude bone metastases. 6 Fluorine-18 fluorodeoxyglucose position emission tomography (FDG-PET) was recently reported to increase the detection sensitivity for both skeletal metastases and therapeutic responses. 2 When detecting bone metastases, FDG-PET may be more sensitive than whole-body MRI scans. 6 FDG is a glucose analogue used as a metabolic tracer to detect focal sites of high metabolic activity that are suggestive of tumors. 19, 20 Anatomic markers in FDG-PET are organs of high metabolic activity such as the brain and excretory system. 20 On PET/CT, using the GE Discovery ST (GE Medical Systems, Waukesha, WI), the images for Figures 5 and 6 were acquired. Figure 5 is a coronal view acquired posterior in the body to view the left thigh mass, and Figure 6 is a coronal view acquired anterior in the body to view the pelvic mass. Figure 5 demonstrates heterogeneous FDG uptake and central photopenia in a left thigh mass. In Figure 6 , tumor mass effect displaces the urinary bladder cranially in the right pelvis. The color bar on the images (Figures 5 and 6) represents metabolic activity. The more intense a structure or the brighter it appears, the higher the metabolic rate, or the aggressiveness, of the structure.
Recommended Therapies
The standard for treatment of Ewing sarcoma is a multimodal therapeutic regimen, including a combination of chemotherapy, surgery, and radiotherapy. Before the age of chemotherapy, fewer than 10% of patients with Ewing sarcoma survived, despite the well-known radiosensitivity of this tumor. 6 Systemic chemotherapy is for eradicating microscopic disease, and radiation therapy and surgery are for control of the primary lesion. 5 The efficacy of chemotherapy appears to be closely dependent on the stage of the cancer. 7 The primary tumor location is the most important factor when determining prognosis, with nonpelvic tumors having better outcomes. 5 The treatment options for local control continue to be radiation or surgery or a combination of both. 6 The most influential factor related to surgical success is the resection margins. The wider the resection margins, the lower the rate of local tumor recurrence. 5 Surgical options include limb salvage and amputation. 5 Both MRI and CT play great roles in determining tumor extent prior to surgical procedures. An MRI (Figure 7) demonstrates a large thigh mass likely involving the hamstrings. On CT imaging, Figure 8 depicts a large, lobulated pelvic mass that appears to arise from the external iliac region. The urinary bladder, significantly displaced to the right pelvis, appears partially compressed by the mass (Figure 8) .
A limb salvage surgery (LSS) procedure performed in most cases includes local resection and reconstruction. 2 For LSS cases leading to unsatisfactory orthopedic result, amputation is warranted. 6 LSS is not free of complications. For patients undergoing LSS, a potential complication is nonunion of the bones, which is when the bone does not heal, increasing the risk of fractures. 5 Postsurgical complications will require medical imaging. Fractures are common and warrant frequent radiograph follow-up. 21 Sonography should be considered if postoperative infection is suspected. 21 Sonography is also employed for guiding aspiration of suspected infectious areas. 21 According to Babyn et al., 21 sonography is also helpful in confirming the clinical suspicion of soft tissue tumor recurrence, distinguishing cystic from solid lesions, and guiding tumor biopsy.
Chemotherapy use improves survival for patients with localized tumors but has less effect on patient survival if metastases are present at diagnosis. 14 Chemotherapy is employed to treat distant metastases regardless of their identification at initial staging. 2 Current anticancer drugs proven effective against Ewing sarcoma are doxorubicin, cyclophosphamide, vincristine, actinomycin-D, ifosfamide, and etoposide. 2 Chemotherapeutic drugs damage cells as they divide, and therefore a combination of drugs is administered to destroy cells in different stages of cell division, increasing the likelihood of killing more cancer cells. 22 In the United States, the most common regimen is two alternating combinations of drugs given every two to four weeks. 4 The twoto four-week cycles are given for at least 8 to 12 weeks prior to surgery or radiation and given afterward as well. 4 Another treatment strategy for Ewing sarcoma is highdose chemotherapy with autologous hematopoietic stem cell rescue (HDT). 6 Because this approach may be toxic, most studies investigate HDT for very high-risk patients, most commonly with metastatic disease at diagnosis or following recurrence. 6 Currently, this treatment is only being performed in controlled clinical settings.
Angiogenesis is the formation of new blood vessels and plays a role in the growth and spread of cancer. The new vasculature feeds the cancer cells with oxygen and nutrients, providing the cells the necessary fuel to grow, invade surrounding tissue, spread throughout the body, and form new colonies of cancer cells. 23 The use of antiangiogenic agents to depress this occurrence is being researched. One strategy, termed metronomic chemotherapy, is the chronic administration of low-dose chemotherapy. 14 Chemotherapeutic agents can target the endothelial cells lining the newly formed blood vessels. 24 Evidence suggests that metronomic chemotherapy administered frequently for a prolonged period can hinder angiogenesis by destroying the endothelial lining. 24 After completing the prescribed six months therapy of metronomic chemotherapy, 40% of patients are without toxicity or disease progression, and 16% have partial radiological responses. 14 Sonography is useful in determining the presence of tumor vasculature and predicting histopathologic response to chemotherapy. Color Doppler flow imaging prior to chemotherapy can give baseline information on the tumorfeeding arteries. 25 After the second course of chemotherapy, histopathologic response can be predicted based on Doppler shifts and resistive indexes. 25 Decreased or unaltered resistive indexes in arteries feeding the tumor suggest poor histologic response to chemotherapy in Ewing sarcoma. 25 An increase in resistive index after two cycles of chemotherapy is indicative of a good response. 25 
Prognostic Features
The prognosis of Ewing sarcoma varies with the site of the primary tumor, presence of metastases, and tumor size. According to Lahl et al., 5 the overall five-year disease-free survival rate for localized Ewing sarcoma treated with surgery, radiation, and multiagent chemotherapy is 65% to 76%. When metastases are present at diagnosis, the fiveyear disease-free survival rate decreases to 30%. 5 It becomes quite obvious that the presence of metastatic disease is the most unfavorable prognostic feature. Even with aggressive treatment, patients with metastases have only a 20% chance of long-term survival. 2 The size of the tumor and its location are often interrelated, with patients with larger lesions (greater than 200 mL) having less chance of survival. 6 Other unfavorable prognostic factors include age older than 10 years, poor response to chemotherapy, fever, anemia, leukocytosis, and elevated erythrocyte sedimentation rate. 2
Late Effects
Because of the increased success of treatment, clinicians need to address long-term therapy of Ewing survivors.
These individuals need monitoring for recurrence of disease, and survivors must also be evaluated and educated on potential long-term effects, health issues, and health screening. 5 According to Lahl et al., 5 survivors can suffer from multiple psychosocial sequelae, including but not limited to fear of recurrence, sense of physical damage related to local therapy of limb salvage or amputation, posttraumatic stress disorder, anxiety, depression, difficulties with interpersonal relationships, and financial and employment issues. Health care professionals must provide appropriate supportive services and counseling for those in need of psychosocial intervention. 5 Being able to identify patients at risk for late effects from the sequelae of their treatments is a new challenge to health care professionals because Ewing sarcoma was once a noncurable disease.
